These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37029381)

  • 21. NK cells enhance CAR-T cell antitumor efficacy by enhancing immune/tumor cells cluster formation and improving CAR-T cell fitness.
    Bachiller M; Perez-Amill L; Battram AM; Carné SC; Najjar A; Verhoeyen E; Juan M; Urbano-Ispizua A; Martin-Antonio B
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34433634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NK cell therapy in relapsed refractory multiple myeloma.
    Roshandel E; Ghaffari-Nazari H; Mohammadian M; Salimi M; Abroun S; Mirfakhraie R; Hajifathali A
    Clin Immunol; 2023 Jan; 246():109168. PubMed ID: 36415020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
    Merino A; Maakaron J; Bachanova V
    Blood Rev; 2023 Jul; 60():101073. PubMed ID: 36959057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress on CAR-T cell therapy for hematological malignancies.
    Hu K; Huang Y; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):192-203. PubMed ID: 36161291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges.
    Baghery Saghchy Khorasani A; Yousefi AM; Bashash D
    Int Immunopharmacol; 2022 Sep; 110():109041. PubMed ID: 35839565
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR-NK cell therapy in AML: Current treatment, challenges, and advantage.
    Bahramloo M; Shahabi SA; Kalarestaghi H; Rafat A; Mazloumi Z; Samimifar A; Asl KD
    Biomed Pharmacother; 2024 Aug; 177():117024. PubMed ID: 38941897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
    Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
    Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
    Sun W; Jiang Z; Jiang W; Yang R
    Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAR-T cell therapy for patients with hematological malignancies. A systematic review.
    Pasqui DM; Latorraca CDOC; Pacheco RL; Riera R
    Eur J Haematol; 2022 Dec; 109(6):601-618. PubMed ID: 36018500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition.
    Fetzko SL; Timothy LD; Parihar R
    Curr Hematol Malig Rep; 2023 Dec; 18(6):264-272. PubMed ID: 37751103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies.
    Tanaka J; Miller JS
    Blood Rev; 2020 Nov; 44():100678. PubMed ID: 32229065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Progress in chimeric antigen receptor NK cell therapy for hematological malignancies].
    Wang XD; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1051-1056. PubMed ID: 36709115
    [No Abstract]   [Full Text] [Related]  

  • 34. Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.
    Baumeister SH; Murad J; Werner L; Daley H; Trebeden-Negre H; Gicobi JK; Schmucker A; Reder J; Sentman CL; Gilham DE; Lehmann FF; Galinsky I; DiPietro H; Cummings K; Munshi NC; Stone RM; Neuberg DS; Soiffer R; Dranoff G; Ritz J; Nikiforow S
    Cancer Immunol Res; 2019 Jan; 7(1):100-112. PubMed ID: 30396908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAR NK Cell Therapy for the Treatment of Metastatic Melanoma: Potential & Prospects.
    Hibler W; Merlino G; Yu Y
    Cells; 2023 Nov; 12(23):. PubMed ID: 38067178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chimeric antigen receptor T-cell therapy for hematological malignancies].
    Nakazawa Y
    Rinsho Ketsueki; 2019; 60(9):1351-1357. PubMed ID: 31597863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
    Caruso S; De Angelis B; Del Bufalo F; Ciccone R; Donsante S; Volpe G; Manni S; Guercio M; Pezzella M; Iaffaldano L; Silvestris DA; Sinibaldi M; Di Cecca S; Pitisci A; Velardi E; Merli P; Algeri M; Lodi M; Paganelli V; Serafini M; Riminucci M; Locatelli F; Quintarelli C
    J Hematol Oncol; 2022 Nov; 15(1):163. PubMed ID: 36335396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chimeric Antigen Receptor-Natural Killer Cells: A New Breakthrough in the Treatment of Solid Tumours.
    Pan S; Wang F; Jiang J; Lin Z; Chen Z; Cao T; Yang L
    Clin Oncol (R Coll Radiol); 2023 Mar; 35(3):153-162. PubMed ID: 36437159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.